1. Scrip
  2. >>Business
  3. >>Strategy

Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III

 
• By Mandy Jackson

The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.

SC1911_Spotlight_76770868_1200.jpg
After 160 job cuts and with an Enhanze-only focus, Halozyme will be profitable next year. • Source: Shutterstock

Halozyme Therapeutics Inc.’s only clinical drug candidate PEGPH20 will exit the stage – along with the company’s oncology operations – now that the drug has failed to show an improvement in overall survival versus the standard of care in pancreas cancer in the Phase III HALO-301 clinical trial. The spotlight now will focus entirely on the Enhanze drug delivery platform as Halozyme restructures to support its existing partners, including two with product approvals anticipated next year.

The San Diego-based company announced on 4 November that while first-line treatment with PEGPH20 in combination with Celgene Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.